The study has 2 parts. The first part is open to adults with different types of advanced
cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not
successful. The second part is open to people with non-small cell lung cancer with a specific
mutation in the HER2 gene.
The purpose of the first study part is to find the highest dose of a medicine called BI
1810631 the participants can tolerate. Once this dose is found, it will be used in the second
study part to tests whether BI 1810631 can make tumours shrink.
In this study, BI 1810631 is given to people for the first time. Participants take BI 1810631
as tablets once a day or twice a day.
The participants are in the study for as long as they benefit from and can tolerate
treatment. Study doctors regularly check the participants' health and monitor the tumours.
The doctors also take note of any unwanted effects that could have been caused by BI 1810631.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.